13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02259361 (ClinicalTrials.gov) | November 2014 | 1/10/2014 | Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS | Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study | Multiple Sclerosis | Drug: Sustained-release oral dalfampridine;Drug: Placebo | Sheba Medical Center | NULL | Not yet recruiting | 18 Years | 70 Years | Both | 30 | Phase 4 | Israel |